A Study of CM336 in Patients With Relapsed or Refractory Multiple Myeloma

This is a multi-center, open-label, Phase 1/2 study in China to evaluate the safety, tolerability, efficacy, pharmacokinetics, pharmacodynamics and immunogenicity of CM336 in patients with relapsed or refractory multiple myeloma. This study consists of a dose escalation part (Phase 1) and a dose extension part (Phase 2 ). The safety and tolerability of CM336 will be evaluated in Phase 1 study, as well as the maximum tolerated dose (MTD) and the recommended dose level for Phase 2 study will be determined. The efficacy of CM336 will be evaluated in Phase 2 study.

Trial Details

NCT ID
NCT05299424
Phase
PHASE1 / PHASE2
Sponsor
Keymed Biosciences Co.Ltd
Status
RECRUITING
Cancer Type
Relapsed/Refractory Multiple Myeloma
Interventions
  • CM336_group 1
  • CM336_group 2a
  • CM336_group 2b
  • CM336_group 3a
  • CM336_group 3b
  • CM336_group 4a
Locations (sample)
  • Beijing, Beijing Municipality, China|39.9075,116.39723

Key Eligibility Criteria

  • Eastern Cooperative Oncology Group Performance Status (ECOG) of 0-2.
  • Patients with relapsed or refractory MM who have failed or are intolerant to all therapies with known clinical benefit; patients must have received…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Relapsed/Refractory Multiple Myeloma Trials on Trialify →